Highlights
IIA supported (ever)1 patentProfile claimed by owner
About
Treatment of Parkinsons-related Depression
N2B Ltd is developing an intranasal delivery formulation of the approved drug Rasagiline for the treatment of depression associated with Parkinsons disease (PD). The company is on a quick regulatory pathway for NDA submission through the U.S. FDA 5O5(b)(2) approach. N2Bs preclinical results indicate that intranasal delivery of Rasagiline could provide both a useful alternative to oral administration in the treatment of PD and a novel therapeutic approach for the treatment of depression in PD patients. N2B was founded as an incubator company of Youdim Pharmaceuticals.
Identity
| Name | N2B |
|---|---|
| Slug | n2b |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgIGTnYMKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Aug 2017 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Yokne'am Illit |
| HQ address | Yokne'am Illit, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical DevicesMedical Treatment & Therapeutics
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcarePatients
Business models
B2B
Tags
pharmaceuticalsmental-healthdegenerative-diseasesneurologyparkinsontreatments
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}